Lv1
100 积分 2025-09-02 加入
Novel Highly Potent c-Met Degraders against a Broad Range of Cancers
1个月前
已完结
Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy
1个月前
已完结
A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer
1个月前
已完结
Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
1个月前
已完结
Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells
1个月前
已完结
P1.12A.07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation
2个月前
已关闭
Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial
2个月前
已完结
Absorption, metabolism, and excretion of oral [14C] radiolabeled donafenib: an open-label, phase I, single-dose study in humans
2个月前
已完结
The Molecular Basis of Pancreatic Fibrosis Common Stromal Gene Expression in Chronic Pancreatitis and Pancreatic Adenocarcinoma
2个月前
已撤回
Amendments to the Perceived Restorative Components Scale for Children (PRCS-C II)
2个月前
已采纳
Discovery and Characterization of Small Molecule Inhibitors Targeting Exonuclease 1 for Homologous Recombination-Deficient Cancer Therapy
2个月前
已采纳
皖公网安备34019202002308
